The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload
Open accessAbstract
The cardiac pathological response to sustained pressure overload involves myocyte hypertrophy and dysfunction along with interstitial changes such as fibrosis and reduced capillary density. These changes are orchestrated by mechanical forces and factors secreted between cells. One such secreted factor is TGF-β, which is generated by and interacts with multiple cell types. Here we have shown that TGF-β suppression in cardiomyocytes was required to protect against maladaptive remodeling and involved noncanonical (non-Smad-related) signaling. Mouse hearts subjected to pressure overload and treated with a TGF-β-neutralizing Ab had suppressed Smad activation in the interstitium but not in myocytes, and noncanonical (TGF-β-activated kinase 1 [TAK1]) activation remained. Although fibrosis was greatly reduced, chamber dysfunction and dilation persisted. Induced myocyte knockdown of TGF-β type 2 receptor (TβR2) blocked all maladaptive responses, inhibiting myocyte and interstitial Smad and TAK1. Myocyte knockdown of TβR1 suppressed myocyte but not interstitial Smad, nor TAK1, modestly reducing fibrosis without improving chamber function or hypertrophy. Only TβR2 knockdown preserved capillary density after pressure overload, enhancing BMP7, a regulator of the endothelial-mesenchymal transition. BMP7 enhancement also was coupled to TAK1 suppression. Thus, myocyte targeting is required to modulate TGF-β in hearts subjected to pressure overload, with noncanonical pathways predominantly affecting the maladaptive hypertrophy/dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Molecular Mechanisms of Myocardial Remodeling
SWYNGHEDAUW, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.215 · Cited by 1,460
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Hein, S., Arnon, E., Kostin, S., Schönburg, M., Elsässer, A., Polyakova, V., Bauer, E. P., Klövekorn, W.-P., & Schaper, J. (2003) · Circulation · doi:10.1161/01.cir.0000051865.66123.b7 · Cited by 1,102
Cardiac Fibroblast: The Renaissance Cell
Souders, C. A., Bowers, S. L. K., & Baudino, T. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209809 · Cited by 984
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Harada, M., et al. (2007) · Nature · doi:10.1038/nature05602 · Cited by 905
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Takimoto, E., Champion, H. C., Li, M., Belardi, D., Ren, S., Rodriguez, E. R., Bedja, D., Gabrielson, K. L., Wang, Y., & Kass, D. A. (2005) · Nature Medicine · doi:10.1038/nm1175 · Cited by 903
Self-citation
Cited by
Mechanisms of physiological and pathological cardiac hypertrophy
Nakamura, M., & Sadoshima, J. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0007-y · Cited by 1,658
Cardiac Fibrosis: The Fibroblast Awakens
Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., & Blaxall, B. C. (2016) · Circulation Research · doi:10.1161/circresaha.115.306565 · Cited by 1,596
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
“Indeed, cardiomyocyte-specific deletion of Tgfbr2 from the hearts of mice blocked maladaptive responses to pressure overload stimulation, inhibiting myocyte and interstitial Smad signaling and fibrosis (27).”
InfluentialCardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease
Fan, D., Takawale, A., Lee, J., & Kassiri, Z. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-15 · Cited by 814
Chronic Heart Failure and Inflammation: What Do We Really Know?
Dick, S. A., & Epelman, S. (2016) · Circulation Research · doi:10.1161/circresaha.116.308030 · Cited by 692
Hypoxia-Inducible Factor 1 and Cardiovascular Disease
Semenza, G. L. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170322 · Cited by 608
The Extracellular Matrix in Ischemic and Nonischemic Heart Failure
Frangogiannis, N. G. (2019) · Circulation Research · doi:10.1161/circresaha.119.311148 · Cited by 520
Heart Failure With Preserved Ejection Fraction: Mechanisms, Clinical Features, and Therapies
Sharma, K., & Kass, D. A. (2014) · Circulation Research · doi:10.1161/circresaha.115.302922 · Cited by 508
Self-citationSchirone, L., Forte, M., Palmerio, S., Yee, D., Nocella, C., Angelini, F., Pagano, F., Schiavon, S., Bordin, A., Carrizzo, A., et al. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3920195 · Cited by 425
Extracellular matrix remodeling and cardiac fibrosis
Li, L., Zhao, Q., & Kong, W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.013 · Cited by 419
Inflammation and fibrosis in murine models of heart failure
Bacmeister, L., Schwarzl, M., Warnke, S., Stoffers, B., Blankenberg, S., Westermann, D., & Lindner, D. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0722-5 · Cited by 382
A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In Vivo
Davis, J., Burr, A. R., Davis, G. F., Birnbaumer, L., & Molkentin, J. D. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.08.017 · Cited by 358
Myofibroblasts: Trust your heart and let fate decide
Davis, J., & Molkentin, J. D. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.10.019 · Cited by 345
Transforming growth factor-β in myocardial disease
Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 344
Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling
Frieler, R. A., & Mortensen, R. M. (2015) · Circulation · doi:10.1161/circulationaha.114.008788 · Cited by 334
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Gourdie, R. G., Dimmeler, S., & Kohl, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.89 · Cited by 332
Role of cytokines and inflammation in heart function during health and disease
Bartekova, M., Radosinska, J., Jelemensky, M., & Dhalla, N. S. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9716-x · Cited by 293
Shah, A. M., & Mann, D. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60894-5 · Cited by 284
Cavalera, M., Wang, J., & Frangogiannis, N. G. (2014) · Translational Research · doi:10.1016/j.trsl.2014.05.001 · Cited by 267
Duan, Q., McMahon, S., Anand, P., Shah, H., Thomas, S., Salunga, H. T., Huang, Y., Zhang, R., Sahadevan, A., Lemieux, M. E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5084 · Cited by 262
Immune Mechanisms in Heart Failure
Zhang, Y., Bauersachs, J., & Langer, H. F. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.942 · Cited by 262
Tarantini, S., Tucsek, Z., Valcarcel-Ares, M. N., Toth, P., Gautam, T., Giles, C. B., Ballabh, P., Wei, J. Y., Wren, J. D., Ashpole, N. M., et al. (2016) · AGE · doi:10.1007/s11357-016-9931-0 · Cited by 98
Josowitz, R., Mulero-Navarro, S., Rodriguez, N. A., Falce, C., Cohen, N., Ullian, E. M., Weiss, L. A., Rauen, K. A., Sobie, E. A., & Gelb, B. D. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.018 · Cited by 45
Zhang (2015) · doi:10.1242/dmm.021303 · Cited by 9
Metadata
- Authors
- Koitabashi, N., Danner, T., Zaiman, A. L., Pinto, Y. M., Rowell, J., Mankowski, J., Zhang, D., Nakamura, T., Takimoto, E., & Kass, D. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2301-2312
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2074156641
- Cited by
- 334
- References
- 49
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.